Seeking Alpha

Sarepta Therapeutics (SRPT) +8% to $29.16 after Piper Jaffray says the biotech has the potential...

Sarepta Therapeutics (SRPT) +8% to $29.16 after Piper Jaffray says the biotech has the potential to be a $160/share stock, although its nearer-term range could be $60-$80. Efsinvestment's Ahmed Ishtiaq wrote on Seeking Alpha this week that Sarepta is "ready to move higher." The company's lead drug is Eteplirsen for the treatment of Duchenne muscular dystrophy, which looks like it could be a blockbuster.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs